Article Text

Download PDFPDF
Rare complication of doxorubicin-induced complete heart block in a patient with Hodgkin’s lymphoma: a case report
  1. Manjappa Mahadevappa1,2,
  2. Kiran Pura Krishnamurthy3,
  3. Lakshay Kumar Attri4,
  4. Yogitha Chandrappa5,
  5. Prashanth Kulkarni6
  1. 1Cardiology, JSS Medical College, Mysuru, Karnataka, India
  2. 2Cardiology, JSS Hospital, Mysuru, Karnataka, India
  3. 3Oncology, JSS Medical College, Mysuru, Karnataka, India
  4. 4Pharmacy Practice, JSS College of Pharmacy, Mysuru, Karnataka, India
  5. 5Medicine, JSS Medical College, Mysuru, Karnataka, India
  6. 6Cardiology, Heart Care Centre, SVP Nagar, Bidar, Karnataka, India
  1. Correspondence to Dr Manjappa Mahadevappa, Cardiology, JSS Medical College, Mysuru, Karnataka 570015, India; manjappam{at}


Anthracyclines are associated with cardiotoxic manifestations that are mainly dose-dependent, with onset varying from a few days to many years after stopping treatment. Frequent monitoring for toxic manifestations, early detection, cessation of anthracycline use and appropriate treatment is the key to preventing morbidity and mortality. Complete heart block with doxorubicin use in Hodgkin’s lymphoma is rarely reported, and is a severe toxic manifestation necessitating withdrawal or changing of regimen to etoposide + bleomycin + vinblastine + dacarbazine (EBVD), as in this case.

  • Heart failure
  • Case Reports
  • Antineoplastic agents

Data availability statement

Data are available upon request.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.